Early versus delayed autologous stem cell transplantation in patients receiving novel therapies for Multiple Myeloma

Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However the timing of ASCT in the era of novel agents (lenalidomide, thalidomide, bortezomib) is unknown. We retrospectively reviewed the outcome of MM patients who received novel agent based induction treatm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dunavin, Neil C., Wei, Lai, Elder, Patrick, Phillips, Gary S, Benson, Don M, Hofmeister, Craig C., Penza, Sam, Greenfield, Carli, Rose, Karen S., Rieser, Gisele, Merritt, Lisa, Ketcham, Jill, Heerema, Nyla, Byrd, John C., Devine, Steven M., Efebera, Yvonne A.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3769940/
https://ncbi.nlm.nih.gov/pubmed/23194056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.751528
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars